SEC Tracker
Get the app

Alamar Biosciences ALMR

Alamar Biosciences Q1 FY26: revenue $26.0M; diluted EPS −$1.74

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Alamar Biosciences reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$26.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$21.3MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$1.74No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$64.6MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations−$20.3MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Alamar Biosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3826 and related industry codes: the same peer list as the financial tables.

  1. Owlet OWLT public float $96M, Jun 30, 2025
  2. Aehr Test Systems AEHR public float $671M, Nov 28, 2025
  3. Quanterix QTRX public float $239M, Jun 30, 2025
  4. Intest INTT public float $85M, Jun 30, 2025
  5. Sypris Solutions SYPR public float $28M, Jun 29, 2025

Data on this page was fetched . The filing on SEC.gov is the record.